Newswise — A new perspective article in the March 2018 issue of SLAS Discovery from the biology group at the European Screening Centre Newhouse details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.

MST measures the rate and direction of movement of biomolecules through a temperature gradient, which can change when small molecules bind to them. The authors describe the MST technology, their assay development and screening workflows, lessons learned and compare the success of MST with other common biophysical assay techniques.

Developing the use of such relatively new technologies is critically important to improving the efficiency of drug discovery. According to the authors, most drug discovery professionals have war stories of trying to develop hit compounds only to have experienced crashing disappointment, often at great expense, as it became apparent the compounds were affecting the target protein through some spurious, unproductive and ultimately undevelopable mechanism. 

The ELF provides a unique perspective in evaluating the usefulness of MST in avoiding this unpleasant dead-end due to the scale of their activities and the large number and variety of targets that have been worked on. 


Using Microscale Thermophoresis to Characterize Hits from High-Throughput Screening: A European Lead Factory Perspective is available for free at SLAS Discovery Online ( For more information about SLAS and its journals, visit

A PDF of this article is available to credentialed media outlets upon request. Contact [email protected]

About our Society and Journals

SLAS (Society for Laboratory Automation and Screening) is an international community of nearly 20,000 professionals and students dedicated to life sciences discovery and technology. The SLAS mission is to bring together researchers in academia, industry and government to advance life sciences discovery and technology via education, knowledge exchange and global community building.

SLAS DISCOVERY: 2016 Impact Factor 2.444. Editor-in-Chief Robert M. Campbell, Ph.D., Eli Lilly and Company, Indianapolis, IN (USA). SLAS Discovery (Advancing Life Sciences R&D) was previously published (1996-2016) as the Journal of Biomolecular Screening (JBS).

SLAS TECHNOLOGY: 2016 Impact Factor 2.850. Editor-in-Chief Edward Kai-Hua Chow, Ph.D., National University of Singapore (Singapore). SLAS Technology (Translating Life Sciences Innovation) was previously published (1996-2016) as the Journal of Laboratory Automation (JALA).

Follow SLAS on Twitter at @SLAS_Org.

Follow SLAS on Facebook at SocietyforLaboratoryAutomationandScreening.

Follow SLAS on YouTube at SLASvideo. 

Follow SLAS Americas on LinkedIn at Society for Laboratory Automation and Screening (SLAS Americas). 

Follow SLAS Europe on LinkedIn at Society for Laboratory Automation and Screening Europe (SLAS Europe).